Prevalence of Metabolic Syndrome in Patient With Cardiovascular Disease in AL- Thawra Hospital sanaa Yemen

Abstract

  Metabolic syndrome (Met S) has been defined in different ways. However, key components common to most definitions are a constellation of risk factors including abdominal adiposity, impaired fasting glucose, hypertension, and dyslipidemia. A major mediator of  Met S appears to be insulin resistance, which relates to the development of the vascular and metabolic dysfunctions that precede overt cardiovascular disease and type 2 diabetes. Evidence suggests that the mechanisms underlying the elevated cardiovascular risk associated with Met S begin with subclinical organ damage. Therapy for Met S targets individual components of the syndrome and includes lifestyle interventions, lipid-modifying therapy, and antihypertensive agents, particularly those that inhibit the renin-angiotensin system. Results of trials of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have demonstrated reductions in new-onset diabetes and cardiovascular events in a wide range of patients. Clinical trials to investigate further the role of these drugs in the primary prevention of type 2 diabetes in patients with Met S are currently under way. The purpose of this research is   to determine the prevalence between metabolic syndrome in patient with  cardiovascular disease in Al-Thawra hospital , Yemen Sana'a.